Skip to main content

Table 4 Injection of pGL3-basic- hTERTp-TK- EGFP- CMV/GCV inhibited tumor development in vivo

From: Targeted gene therapy of nasopharyngeal cancer in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer

Sample Animals Tumor volume at day 39 (cm3) Tumor weight at day 39 (g) Inhibition rate
Blank 5 6.23 ± 0.04 2.68 ± 0.02 /
Non-enhanced group 5 3.51 ± 0.02 1.51 ± 0.01 43.68%*
Enhanced group/GCV 5 2.72 ± 0.02 1.17 ± 0.01 56.34%*
Enhanced group 5 5.80 ± 0.13 2.51 ± 0.05 6.48%*
GCV group 5 5.98 ± 0.09 2.56 ± 0.09 4.32%*
Lipofectamine group 5 5.83 ± 0.14 2.51 ± 0.02 6.41%*
  1. Data are expressed as mean ± standard deviation from three experiments. * indicates p < 0.0001 compared with the other group.